Amgen is a multinational biopharmaceutical company based in Thousand Oaks, California, United States. It was founded in 1980 by a group of venture capitalists led by William K. Bowes Jr., who aimed to create a pioneering biotechnology company focused on the development of innovative medicines.

The company's headquarters, located in Thousand Oaks, spans over 700,000 square feet and serves as the central hub for research and development, manufacturing, and administration. With an emphasis on sustainability, the campus incorporates green building practices and extensive use of renewable energy sources. Amgen is primarily engaged in the development and commercialization of human therapeutics.

The company's product portfolio spans a wide range of therapeutic areas, including oncology, cardiovascular disease, neuroscience, inflammation, and bone health. Notable products include Enbrel, Neulasta, Prolia, Repatha, and Xgeva. Operating on a global scale, Amgen has established numerous subsidiaries, joint ventures, and partnerships to enhance its presence and expand its reach.

Notable subsidiaries include Amgen Australia, Amgen Canada, Amgen Europe B. V., and Amgen Manufacturing Limited in Ireland. Additionally, strategic collaborations with other pharmaceutical companies, research institutions, and academia have helped to advance Amgen's research and development capabilities.

Amgen holds a prominent position in the biopharmaceutical industry with its significant market presence and high global sales. The company consistently ranks among the top biotechnology companies globally, competing with major players like Pfizer, Roche, and Johnson & Johnson. With a robust product pipeline and a focus on innovation, Amgen continues to strengthen its market position and contribute to advancements in healthcare around the world.

Over the years, Amgen has achieved numerous milestones and advancements in the biotechnology field. The company's commitment to scientific excellence and patient care has led to several breakthrough therapies that have improved the lives of millions of patients worldwide. One notable achievement was the development of the first targeted cancer therapy, Imatinib, which revolutionized the treatment of chronic myeloid leukemia.

Currently, Amgen remains a leading force in the biopharmaceutical industry, continually investing in research and development to bring innovative therapies to patients in need. The company's latest updates and key information can be found through its official website and press releases, which provide insights into ongoing clinical trials, regulatory approvals, and partnerships. In conclusion, Amgen is an influential biopharmaceutical company headquartered in Thousand Oaks, California.

With a diverse product portfolio, global operations, and a strong market position, Amgen continues to make significant contributions to the advancement of healthcare and the treatment of various diseases